OA21.05 Tepotinib + Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis

Tepotinib (a MET TKI) + osimertinib has shown promising efficacy in patients with EGFRm METamp NSCLC, who have a high unmet need after 1L osimertinib. We report the primary analysis of tepotinib + osimertinib from INSIGHT 2 (NCT03940703) in patients with ≥9 months' follow-up (data-cut: March 28, 2023). Given the higher incidence of EGFRm NSCLC in Asia, outcomes among patients enrolled in Asia are also reported.